Welcoming you for any type of article submission for the upcoming issue on/before February 26, 2021.

Mini Review
Volume 5 Issue 11 - 2020
The Role of Sodium-Glucose Co-Transporter-2 Inhibitors in Heart Failure
Samuel M John1*, Adrian Gavre2 and Chinyere Ukegbu2
1Associate Professor of Pharmacy Practice, Department of Pharmacy Practice, Philadelphia College of Osteopathic Medicine, School of Pharmacy, Suwanee, Georgia, United States
2PharmD Candidate, Department of Pharmacy Practice, PharmD candidate, School of Pharmacy, Suwanee, Georgia, United States
*Corresponding Author: Samuel M John, Associate Professor of Pharmacy Practice, Department of Pharmacy Practice, Philadelphia College of Osteopathic Medicine, School of Pharmacy, Suwanee, Georgia, United States.
Received: October 02, 2020; Published: October 15, 2020


Introduction: Long standing chronic conditions such as Type 2 diabetes have been a known risk factor in the development of cardiovascular disease. The Food and Drug Administration’s (FDA) guidance issued in 2008 for all new antidiabetic medications to undergo large cardiovascular studies came about due to safety concerns with certain classes of diabetic agents, which prompted drug manufacturers to conduct several well-known large clinical studies evaluating safety and efficacy of these drugs in relation to cardiovascular disease and adverse effects.

Discussion: The benefits of sodium-glucose cotransporter-2 (SGLT2) inhibitors are thought to be due to its mechanism of action in promoting natriuretic and diuretic effects resulting in lowering blood pressure and reducing blood plasma volume. Clinical studies starting with the Canagliflozin in the Canagliflozin Cardiovascular Assessment Study (CANVAS) along with its sister trial CANVAS R were evaluated in the CANVAS Program, Empagliflozin in the EMPA-REG Outcome, Dapagliflozin in both the DECLARE-TIMI 58 and most recently the DAPA-HF trial showed a benefit when these agents were added to standard therapy in terms of reducing hospitalization for heart failure.

Conclusion: The recent FDA approval of dapagliflozin as an adjunct agent in patients with heart failure with reduced ejection fraction marks the first time that an antidiabetic medication has been granted an indication other than for diabetes. This certainly offers clinicians who treat patients with heart failure an additional option in optimizing medication regimens and managing symptoms. Economic factors as well as adverse events should be assessed with this class of medication when used as additional therapy. Future clinical studies evaluating SGLT2-inhibitors and its benefit in cardiovascular outcomes may continue to provide more promising options to clinicians in managing cardiovascular disorders.

Keywords: Type 2 Diabetes; Food and Drug Administration’s (FDA); Sodium-Glucose Cotransporter-2 (SGLT2)


  1. Centers for Disease Control and Prevention. National Diabetes Statistics Report. Atlanta, GA: Centers for Disease Control and Prevention, U.S. Dept of Health and Human Services (2020).
  2. Regier E., et al. “More than 7 years of Hindsight: Revisiting the FDA’s 2008 Guidance on Cardiovascular Outcomes Trials for Type 2 Diabetes Medications”. Clinical Diabetes 4 (2016): 173-180.
  3. Food and Drug Administration (FDA). FDA approves new treatment for a type of heart failure (FDA News Release) (2020).
  4. Virani SS., et al. “Heart disease and stroke statistics-2020 update: a report from the American Heart Association”. Circulation9 (2020): e139-e596.
  5. Benjamin EJ., et al. “Heart disease and stroke statistics-2019 update: a report from the”. American Heart Association10 (2019): e56-e528.
  6. Yancy CW., et al. “2017ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America”. Circulation 136 (2017): e137-e161.
  7. Majewski C and Bakris GL. “Blood pressure reduction: an added benefit of sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes”. Diabetes Care 38 (2015): 429-430.
  8. Gerstein HC., et al. “Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double blind, randomized placebo-controlled trial”. Lancet10193 (2019): 121-130.
  9. Marso SP., et al. “Liraglutide and cardiovascular outcomes in type 2 diabetes”. The New England Journal of Medicine 375 (2016): 311-322.
  10. Marso SP., et al. “Semaglutide and cardiovascular outcomes in patients with type 2 diabetes”. The New England Journal of Medicine 375 (2016): 1834-1844.
  11. Zinman B., et al. “Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes”. The New England Journal of Medicine 373 (2015): 2117-2128.
  12. Neal B., et al. “Canagliflozin and cardiovascular and renal events in type 2 diabetes”. The New England Journal of Medicine 377 (2017): 644-657.
  13. Wiviott SD., et al. “Dapagliflozin and cardiovascular outcomes in type 2 diabetes”. The New England Journal of Medicine 380 (2019): 347-357.
  14. McMurray JJV., et al. “Dapagliflozin in patients with Heart Failure and Reduced Ejection Fraction”. The New England Journal of Medicine 381 (2019): 1995-2008.
  15. Peters AL., et al. “Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium-glucose cotransporter-2 inhibition”. Diabetes Care 38 (2015): 1687-1693.
  16. Lupsa BC and Inzucchi SE. “Use of SGLT2 inhibitors in type 2 diabetes: weighing the risks and benefits”. Diabetologia 61 (2018): 2118-2125.
  17. Food and Drug Administration (FDA). FDA removes Boxed Warning about risk of leg and foot amputations for the diabetes medicine canagliflozin (Invokana, Invokamet, Invokamet XR) (2020).
Citation: Samuel M John., et al. “The Role of Sodium-Glucose Co-Transporter-2 Inhibitors in Heart Failure. EC Endocrinology and Metabolic Research. 5.11 (2020): 16-21.

PubMed Indexed Article

EC Pharmacology and Toxicology
LC-UV-MS and MS/MS Characterize Glutathione Reactivity with Different Isomers (2,2' and 2,4' vs. 4,4') of Methylene Diphenyl-Diisocyanate.

PMID: 31143884 [PubMed]

PMCID: PMC6536005

EC Pharmacology and Toxicology
Alzheimer's Pathogenesis, Metal-Mediated Redox Stress, and Potential Nanotheranostics.

PMID: 31565701 [PubMed]

PMCID: PMC6764777

EC Neurology
Differences in Rate of Cognitive Decline and Caregiver Burden between Alzheimer's Disease and Vascular Dementia: a Retrospective Study.

PMID: 27747317 [PubMed]

PMCID: PMC5065347

EC Pharmacology and Toxicology
Will Blockchain Technology Transform Healthcare and Biomedical Sciences?

PMID: 31460519 [PubMed]

PMCID: PMC6711478

EC Pharmacology and Toxicology
Is it a Prime Time for AI-powered Virtual Drug Screening?

PMID: 30215059 [PubMed]

PMCID: PMC6133253

EC Psychology and Psychiatry
Analysis of Evidence for the Combination of Pro-dopamine Regulator (KB220PAM) and Naltrexone to Prevent Opioid Use Disorder Relapse.

PMID: 30417173 [PubMed]

PMCID: PMC6226033

EC Anaesthesia
Arrest Under Anesthesia - What was the Culprit? A Case Report.

PMID: 30264037 [PubMed]

PMCID: PMC6155992

EC Orthopaedics
Distraction Implantation. A New Technique in Total Joint Arthroplasty and Direct Skeletal Attachment.

PMID: 30198026 [PubMed]

PMCID: PMC6124505

EC Pulmonology and Respiratory Medicine
Prevalence and factors associated with self-reported chronic obstructive pulmonary disease among adults aged 40-79: the National Health and Nutrition Examination Survey (NHANES) 2007-2012.

PMID: 30294723 [PubMed]

PMCID: PMC6169793

EC Dental Science
Important Dental Fiber-Reinforced Composite Molding Compound Breakthroughs

PMID: 29285526 [PubMed]

PMCID: PMC5743211

EC Microbiology
Prevalence of Intestinal Parasites Among HIV Infected and HIV Uninfected Patients Treated at the 1o De Maio Health Centre in Maputo, Mozambique

PMID: 29911204 [PubMed]

PMCID: PMC5999047

EC Microbiology
Macrophages and the Viral Dissemination Super Highway

PMID: 26949751 [PubMed]

PMCID: PMC4774560

EC Microbiology
The Microbiome, Antibiotics, and Health of the Pediatric Population.

PMID: 27390782 [PubMed]

PMCID: PMC4933318

EC Microbiology
Reactive Oxygen Species in HIV Infection

PMID: 28580453 [PubMed]

PMCID: PMC5450819

EC Microbiology
A Review of the CD4 T Cell Contribution to Lung Infection, Inflammation and Repair with a Focus on Wheeze and Asthma in the Pediatric Population

PMID: 26280024 [PubMed]

PMCID: PMC4533840

EC Neurology
Identifying Key Symptoms Differentiating Myalgic Encephalomyelitis and Chronic Fatigue Syndrome from Multiple Sclerosis

PMID: 28066845 [PubMed]

PMCID: PMC5214344

EC Pharmacology and Toxicology
Paradigm Shift is the Normal State of Pharmacology

PMID: 28936490 [PubMed]

PMCID: PMC5604476

EC Neurology
Examining those Meeting IOM Criteria Versus IOM Plus Fibromyalgia

PMID: 28713879 [PubMed]

PMCID: PMC5510658

EC Neurology
Unilateral Frontosphenoid Craniosynostosis: Case Report and a Review of the Literature

PMID: 28133641 [PubMed]

PMCID: PMC5267489

EC Ophthalmology
OCT-Angiography for Non-Invasive Monitoring of Neuronal and Vascular Structure in Mouse Retina: Implication for Characterization of Retinal Neurovascular Coupling

PMID: 29333536 [PubMed]

PMCID: PMC5766278

EC Neurology
Longer Duration of Downslope Treadmill Walking Induces Depression of H-Reflexes Measured during Standing and Walking.

PMID: 31032493 [PubMed]

PMCID: PMC6483108

EC Microbiology
Onchocerciasis in Mozambique: An Unknown Condition for Health Professionals.

PMID: 30957099 [PubMed]

PMCID: PMC6448571

EC Nutrition
Food Insecurity among Households with and without Podoconiosis in East and West Gojjam, Ethiopia.

PMID: 30101228 [PubMed]

PMCID: PMC6086333

EC Ophthalmology
REVIEW. +2 to +3 D. Reading Glasses to Prevent Myopia.

PMID: 31080964 [PubMed]

PMCID: PMC6508883

EC Gynaecology
Biomechanical Mapping of the Female Pelvic Floor: Uterine Prolapse Versus Normal Conditions.

PMID: 31093608 [PubMed]

PMCID: PMC6513001

EC Dental Science
Fiber-Reinforced Composites: A Breakthrough in Practical Clinical Applications with Advanced Wear Resistance for Dental Materials.

PMID: 31552397 [PubMed]

PMCID: PMC6758937

EC Microbiology
Neurocysticercosis in Child Bearing Women: An Overlooked Condition in Mozambique and a Potentially Missed Diagnosis in Women Presenting with Eclampsia.

PMID: 31681909 [PubMed]

PMCID: PMC6824723

EC Microbiology
Molecular Detection of Leptospira spp. in Rodents Trapped in the Mozambique Island City, Nampula Province, Mozambique.

PMID: 31681910 [PubMed]

PMCID: PMC6824726

EC Neurology
Endoplasmic Reticulum-Mitochondrial Cross-Talk in Neurodegenerative and Eye Diseases.

PMID: 31528859 [PubMed]

PMCID: PMC6746603

EC Psychology and Psychiatry
Can Chronic Consumption of Caffeine by Increasing D2/D3 Receptors Offer Benefit to Carriers of the DRD2 A1 Allele in Cocaine Abuse?

PMID: 31276119 [PubMed]

PMCID: PMC6604646

EC Anaesthesia
Real Time Locating Systems and sustainability of Perioperative Efficiency of Anesthesiologists.

PMID: 31406965 [PubMed]

PMCID: PMC6690616

EC Pharmacology and Toxicology
A Pilot STEM Curriculum Designed to Teach High School Students Concepts in Biochemical Engineering and Pharmacology.

PMID: 31517314 [PubMed]

PMCID: PMC6741290

EC Pharmacology and Toxicology
Toxic Mechanisms Underlying Motor Activity Changes Induced by a Mixture of Lead, Arsenic and Manganese.

PMID: 31633124 [PubMed]

PMCID: PMC6800226

EC Neurology
Research Volunteers' Attitudes Toward Chronic Fatigue Syndrome and Myalgic Encephalomyelitis.

PMID: 29662969 [PubMed]

PMCID: PMC5898812

EC Pharmacology and Toxicology
Hyperbaric Oxygen Therapy for Alzheimer's Disease.

PMID: 30215058 [PubMed]

PMCID: PMC6133268

News and Events

December Issue Release

We always feel pleasure to share our updates with you all. Here, notifying you that we have successfully released the November issue of respective journals and the latest articles can be viewed on the current issue pages.

Submission Deadline for Upcoming Issue

ECronicon delightfully welcomes all the authors around the globe for effective collaboration with an article submission for the upcoming issue of respective journals. Submissions are accepted on/before December 23, 2022.

Certificate of Publication

ECronicon honors with a "Publication Certificate" to the corresponding author by including the names of co-authors as a token of appreciation for publishing the work with our respective journals.

Best Article of the Issue

Editors of respective journals will always be very much interested in electing one Best Article after each issue release. The authors of the selected article will be honored with a "Best Article of the Issue" certificate.

Certifying for Review

ECronicon certifies the Editors for their first review done towards the assigned article of the respective journals.

Latest Articles

The latest articles will be updated immediately on the articles in press page of the respective journals.